Genetics plays a critical role in the development and progression of many human diseases. Over the last two decades, advances in genetics and genomics research have enabled researchers to identify more than 5,000 genes associated with diseases, including cancers. Additionally, mutations in specific genes can increase an individual’s risk of a particular disorder, such as cystic fibrosis or breast cancer. Not all diseases are caused by hereditary mutations. Environmental factors, lifestyle choices, and other external influences combine with genetic predispositions to shape disease development. For many diseases, such as heart disease, there are multiple genetic risk factors that interact with lifestyle and environmental factors, such as diet, stress and smoking. However, some diseases are caused by mutations in a single gene. Genes can also affect the severity of the disease, as well as how severe its symptoms are. Examples include Sickle Cell Anemia and Cystic Fibrosis. In many cases, genetic testing can be used to diagnosis genetic diseases, and to screen for the presence of genetic mutations in expecting parents or adults. This allows individuals to make proactive decisions about their healthcare, such as whether to pursue preventive care. In some cases, genetic testing can also inform healthcare providers of which treatment options should be considered for an individual. In conclusion, genetics plays a critical role in the development and progression of many diseases. While not all diseases are caused solely by genetic predispositions, some are. By acknowledging the role of genetics in disease risk, individuals can make informed decisions about their healthcare, and healthcare providers can provide more individualized care when treating a particular illness.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States